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Increased human life expectancy has resulted in larger geriatric population throughout the 
world. Consequently, there is increased prevalence of age-associated neurodegenerative 
diseases including Parkinson’s disease (PD) with serious impact on healthcare. This has 
intensified the scientific research on the pathology and therapy of the central nervous 
system (CNS). Although modern approach in biomedical research has made major 
breakthroughs in understanding the pathological basis of PD, the knowledge about therapy 
is limited. Consequently, PD does not have a permanent cure.  
During recent years, there have been several options for PD therapy including both 
pharmacological and neurosurgical approaches. These strategies are primarily aimed at 
improving the motor symptoms without any major side effects ultimately improving the 
quality of the life of the patient. Drugs such as L-dihydroxyphenyl alanine (levodopa or L-
DOPA) replenish the lost dopamine in the brain in early PD and provide symptomatic relief. 
Apart from L-dopa therapy, other drugs including dopamine receptor agonists, MAO-B 
inhibitors and anti-cholinergic drugs have been utilized in the pharmacotherapy of PD 
(Almeida & Hyson, 2008). But, each class of drugs is limited by potential side effects and motor 
complications with chronic treatment. Further, most PD medications do not effectively tackle 
tremor, postural instability and cognitive deficits. Moreover, most of these drugs are not 
completely effective against degeneration of the remaining dopaminergic neurons (Almeida & 
Hyson, 2008). Due to these serious lacunae, there is a tremendous momentum to develop 
newer treatments involving disease modifying, restorative, possibly curative drugs with lesser 
side effects. Most importantly, these drugs should protect the dying neurons thus preventing 
further neuronal loss. In this direction there have been novel strategies of PD 
pharmacotherapy applicable either as independent therapies or as a supplement with the 
existing therapies. These have been tested in experimental models and although many of these 
molecules show promise, their toxicology, bioavailability and clinical efficacy in human 
subjects needs to be examined thoroughly before application to PD.  
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Neurodegeneration in PD involves multiple pathways such as oxidative stress, mitochondrial 
damage, protein aggregation, neuroinflammation etc. Modern medicine utilizes a well-defined 
chemical molecule(s) for pharmacotherapy which might not be effective against different 
disease pathways. Hence, the challenge is to come up with novel molecules that could 
simultaneously target multiple disease pathways without significant side-effects, be non-toxic 
at higher concentrations and have the ability to cross the blood-brain barrier indicating a 
paradigm shift from monotherapy to multi-therapy based on various targets. Towards this, 
natural phytochemicals which possess medicinal properties are being exploited (Kumar, 2006) 
which has increased the interest in the use of herbal products (Tsao, 2010). Consequently, there 
is increasing support for combination of modern drugs with medicine to evolve better 
therapies. It is interesting to note that although phytochemicals normally function as toxins 
and protect the plant source against damage due to pests and harmful organisms, at the lower 
concentrations consumed by humans, these compounds activate adaptive cellular stress 
responses in vivo (“hormetic mechanisms”) thereby providing cytoprotection against 
exogenous toxins. Such hormetic mechanisms relevant to neuronal survival and improved 
brain function ultimately elevate the levels of antioxidant enzymes, protein chaperones and 
neurotrophic factors (Mattson et al., 2007). Polyphenols from various plant sources form a 
major group of phytochemicals with potential therapeutic and curative properties. 
2. Polyphenols: Structure and biological properties 
Polyphenols are the most widely distributed natural compounds in the plant kingdom. They 
are the secondary metabolites which were originally synthesized to protect the plants 
against microbial attack, pests and ultraviolet radiation. Polyphenols are present in fruits, 
vegetables, oils etc. and provide plants with brilliant colours and fragrance. Polyphenols 
might possess many biologically significant functions with implications for human 
degenerative diseases (Han et al., 2007).  
2.1 Chemistry of Polyphenols 
Polyphenols in general have a phenolic structure with several hydroxyl groups. Natural 
polyphenols vary from simple molecules (viz., phenolic acids) to complex polymeric forms 
(viz., condensed tannins) (Tsao, 2010). Flavonoids are the largest group of polyphenols and 
have been studied extensively. Currently more than 8000 phenolic structures are known and 
among them over 4000 flavonoids have been identified (Bravo, 1998, Cheynier, 2005, 
Harborne &  Williams, 2000).They are classified based on the number of phenolic rings and 
the structural elements that link these rings (Butterfield et al., 2002, Ramassamy, 2006) 
(Figures 1 and 2) as follows:  
a. Phenolic acids: These are non-flavonoid polyphenols that constitute less than 1/3 of the 




Fig. 1. Classification of polyphenols. 
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Fig. 2. Chemical structures of common polyphenols. 
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b. Flavonoids: These represent approximately 2/3 of the polyphenolic content in our diet. 
They have the C6-C3-C6 strucural backbone, of which two are phenolic rings named 
Ring A and Ring B, and one chromane ring (Tsao 2010). Flavonoids are further 
classified based on the oxidation state of the chromane ring into Anthocyanins and 
anthoxanthins. Anthoxanthins are further classified into Flavones, Flavonols, 
Flavonones, Isoflavones, Flavanols (D'Archivio et al., 2007).  
c. Stilbenes: Stilbenes are characterized by the presence of 1,2-diphenylethylene nucleus 
with hydroxyl groups substituted on the aromatic rings (Han et al., 2007). The best 
known compound among Stilbenes is trans-resveratrol.  
d. Tannins: Tannins are water soluble polyphenols and are classified into condensed and 
hydrolysable tannins.  
e. Diferuloylmethanes: Diferuloylmethanes are characterized by two aromatic rings 
substituted with hydroxyls, and linked by aliphatic chain containing carbonyl groups. 
Curcumin is one of the best known polyphenol among diferuloylmethanes. 
Most polyphenols are chemically modified by acetylation, hydroxylation, methoxylation. 
These modifications could significantly influence the physicochemical properties and in vivo 
absorption/degradation of the polyphenols. For e.g., acetylated flavonoids (epicatechin, 
epigallocatechin) are absorbed without deconjugation and hydrolysis (Rice-Evans &  Miller 
1996, Scalbert &  Williamson 2000). Similarly, polyphenols with most antioxidant potential 
possess 3- 6 hydroxyl groups. However, hydroxylation in the C3 position significantly 
inhibits the antioxidant activity and chelation of metals (Huguet et al., 1990, van Acker et al., 
1996). Most polyphenols also exist as glycosides with the addition of sugar and acylated 
sugars at different positions of the polyphenolic structure (one to three moieties per 
polyphenol)  (Tsao, 2010). The attached sugar could be either glucose or rhamnose and each 
glycosylation influences the physicochemical properties and intestinal absorption of the 
polyphenol (Rice-Evans &  Miller, 1996, Scalbert &  Williamson, 2000). Accordingly, if 
polyphenols are glycosylated with glucose/galactose, they will be absorbed through the 
small intestine by specific carriers (Scalbert &  Williamson, 2000). Those containing 
rhamnose cannot be absorbed through the small intestine and are degraded by 
rhamnosidases produced by the colonic microflora. Further, glycosylation of polyphenols 
might decrease their antioxidant properties (Fukumoto &  Mazza, 2000).  
2.2 Biological functions of polyphenols 
Polyphenols might ameliorate neurodegeneration mainly via (i) intrinsic antioxidant 
properties and/or by (ii) modulation of cell signalling pathways that control cell survival, 
death and differentiation (Chen et al., 2000, Molina et al., 2003, Shen et al., 2007, Spencer, 
2007).  
2.2.1 Antioxidant properties 
It has been suggested that consumption of foods or beverages which are rich in polyphenols 
can increase the antioxidant levels in vivo (Frankel et al., 1993). Polyphenols can protect 
against cellular oxidative stress by directly scavenging free radicals and by chelation of 
divalent metal ions. The phenolic hydroxyl groups are potent nucleophiles that neutralize 
free radicals and form aroxyl radicals and this is central to the antioxidant properties of 
polyphenols. The antioxidant potential is enhanced by the vicinal hydroxyl groups 
depending on their number and orientation relative to the electron withdrawing groups 
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such as COOH, CH2COOH, or (CH)2CO2CH (Rice-Evans et al., 1996). The radical 
scavenging activity of polyphenols is measured by Trolox (a water soluble -tocopherol 
analog)-equivalent antioxidant capacity (TEAC) assay and expressed as the millimolar 
concentration of Trolox (TEAC=1) equivalent to the activity of a 1 mM solution of the given 
compound (Rice-Evans et al. 1996). Most of the common polyphenols have higher TEAC 
value compared to the endogenous antioxidant glutathione (GSH), whose TEAC is 1.0.  
Since free divalent metal ions such as iron generate free radicals by fenton reaction, 
chelation of free iron by polyphenols protects neurons from oxidative stress (Li et al., 2010) 
with implications for PD and Alzheimer’s disease (AD) (Sahu &  Gray 1997, Sugihara et al., 
1999). Flavonoids protect against oxidative damage either by forming complexes with iron 
or copper or by direct detoxification due to inherent structural characteristics that enhance 
the antioxidant potential (Bors et al., 1990). 
2.2.2 Modulation of cell signalling pathways 
Beyond antioxidant activities, polyphenols such as curcumin, resveratrol, quercetin and 
other flavonoids modulate cellular signalling pathways, that could affect the gene 
expression and interfere with cell death mechanisms (Williams et al., 2004). Polyphenols 
exert modulatory effects on neurons by selectively interacting with protein kinase and lipid 
kinase signalling cascades such as phosphatidylinositol 3-kinase (PI3 kinase or PI3K)/akt, 
tyrosine kinase, protein kinase C (PKC) and Mitogen activated protein kinase (MAPK) 
pathways (Agullo et al., 1997, Gamet-Payrastre et al., 1999, Matter et al., 1992, Schroeter et 
al., 2002, Spencer et al., 2003, Vlahos et al., 1994). Inhibitory or stimulatory actions at these 
pathways immensely affect the cellular functions by altering the phosphorylation states of 
target molecules and/or by modulating gene expression (Spencer, 2007). Many Polyphenols 
bind to ATP binding sites of proteins (Conseil et al., 1998) like PKC (Gamet-Payrastre et al. 
1999, Kantengwa &  Polla, 1991), protein kinase A (PKA) (Revuelta et al., 1997), calcium 
plasma membrane ATPase, mitochondrial ATPase and topoisomerase (Boege et al., 1996). 
For example, the stilbene resveratrol and the citrus flavones, naringenin and hesperetin have 
been shown to inhibit the activity of a number of protein kinases (Spencer 2007). Flavonoids 
and their metabolites can selectively interact within MAPK signalling pathways (Kobuchi et 
al., 1999, Kong et al., 2000).  
a. Extracellular signal-regulated kinase (ERK) pathway: Some flavonoids are found to 
have inhibitory effect on the ERK pathway and some others activate this pathway. 
Flavonoids have close structural homology to specific inhibitors of ERK pathway, such 
as PD98059 (2’–amino-3’-methoxyflavone), which is a selective non-competitive 
inhibitor of the mitogen activated kinase, MEK 1 (Alessi et al., 1995). Flavonoids and 
their metabolites may also act on this pathway in a similar manner. Certain flavonoids 
such as Quercetin and its O-methylated metabolites are shown to induce neuronal 
apoptosis by inhibition of ERK pathway (Spencer 2003). The MEK inhibitor PD98059 
has been shown to effectively block inducible nitric oxide synthase (iNOS) expression 
and generation of nitric oxide (NO) (Bhat et al., 1998), suggesting that flavonoids may 
also be capable of exerting anti-inflammatory actions via inhibitory actions on MEK1 
within the ERK signalling pathway. Studies have indicated that flavanols (Huang et al., 
2005, Li et al., 2004), flavones (Chen et al., 2004, Kim et al., 2001, Lee et al., 2003, Shen et 
al., 2002, Woo et al., 2006), and flavonols (Chen et al., 2005) are all capable of inhibiting 
the release of NO by activated microglia via the down-regulation of iNOS gene 
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expression. Epicatechin (EC), and one of its metabolites, 3’-O–methyl-(–)- epicatechin 
(mEC), have been shown to stimulate phosphorylation of ERK1/2 and the downstream 
transcription factor cAMP response element binding protein (CREB) at physiological 
concentrations (Schroeter et al., 2007). Some polyphenols may act on the ERK pathway 
via acting through steroid-like receptors in neurons to modulate ERK and CREB-
mediated gene expression. For example, resveratrol rapidly activates ERK signalling 
through alpha and beta estrogen receptors (Klinge et al., 2005).  
b. c-Jun-N-terminal kinase (JNK): There are a number of potential sites where flavonoids 
may interact in the JNK pathway. EC and mEC have been shown to protect neurons 
against oxidative damage via a mechanism involving the suppression of JNK, and 
downstream partners, c-jun and pro-caspase-3 (Schroeter et al., 2001). The flavone, 
baicalein, significantly inhibits 6-hydroxydopamine (6-OHDA) induced JNK activation 
and neuronal cell death and quercetin suppresses JNK activity and apoptosis induced 
by hydrogen peroxide (Ishikawa &  Kitamura 2000), 4-hydroxy-2-nonenal (4HNE) 
(Uchida et al., 1999) and tumour necrosis factor-alpha (TNF-┙) (Kobuchi et al. 1999). 
Flavonoids may inhibit the activation of JNK pathway upstream by decreasing 
oxidative stress and maintaining calcium homeostasis (Davis 1999). They may also 
inhibit JNK activation by modulation of the apoptosis signal-regulating kinase 1 (ASK1) 
phosphorylation state, and its association with 14-3-3 protein, which is essential for 
suppression of cellular apoptosis (Zhang, L. et al., 1999). Investigations have indicated 
that flavonoids might have anti-apoptotic property by blocking oxidative stress induced 
activation of caspase-3 in neurons (Schroeter et al. 2001, Schroeter et al., 2000). 
Flavonoid o-quinones, formed from the intracellular oxidation of flavonoids also inhibit 
JNK and other MAPKs via the nucleophilic addition to the cysteine residues of these 
proteins (Spencer et al., 2004). 
c. PI3 kinase pathway: Flavonoids can modulate signalling through the serine/threonine 
kinase, Akt/PKB, one of the main downstream effectors of PI3K in neuronal survival 
(Coffer et al., 1998). Experimental studies suggest that flavonoids inhibit PI3K via direct 
interactions with its ATP binding site. Indeed, one of the most selective PI3K inhibitors 
available, LY294002, was modelled based on the structure of quercetin (Matter et al. 
1992). 
In the current review, we have discussed the properties and therapeutic potential in PD of 
three important polyphenols: cucumin, resveratrol and tea polyphenols.  
3. Curcumin 
Curcumin, the yellow curry spice from the rhizome of turmeric is a polyphenolic compound 
with several beneficiary properties. Chemically characterized to be diferuloylmethane 
(C21H20O6) or 1,6-heptadiene-3,5-dione-1,7-bis(4-hydroxy-3-methoxyphenyl), curcumin 
exists as a group of compounds called curcuminoids.  
3.1 Absorption 
Although curcumin has several beneficial properties in vivo, a major limiting factor is its 
poor bioavailability. Its poor bioavailability is due to insolubility in aqueous media, poor 
absorption, rapid metabolism and fast systemic elimination. Following oral administration 
of curcumin (1.0 g / kg) in mice, 0.13 g / ml was detected in the plasma after 15 min and 
peaked at 0.22 g / ml at 1 hr. Plasma concentration of curcumin however declined to 5 ng / 
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ml at 6 h. Following intraperitoneal administration of curcumin (0.1 g/kg), only 2.25 g / ml 
appeared in the plasma in the first 15 min. Upto 99% of curcumin and 85% of 
tetrahydrocurcumin was conjugated with glucuronide thus limiting their bioavailability. It 
has also been suggested that oral administration of curcumin results in very low absorption 
into the blood. At 1 h time point, the intestine, spleen, liver and kidney had 177.04, 26.06, 
26.90, and 7.51 g/g curcumin respectively, while the brain had as less as 0.41 g / g. Mass 
spectrometry analysis suggested that curcumin was first biotransformed to 
dihydrocurcumin and then tetrahydrocurcumin which were subsequently converted to 
monoglucuronide conjugates (Pan et al., 1999). In a more recent study, curcumin was 
administered orally to rats at 500 mg / kg and the peak curcumin concentration of ~36 mg / 
whole tissue, in the intestine was reached at 1 h time point, while in the blood, liver and 
kidney, peak concentrations were reached at 6 h (Suresh &  Srinivasan 2010). In a pilot 
human trial on cancer patients, the concentration of curcumin in the liver following oral 
administration (450 – 3600 mg/ day for 1 week prior to surgery) was measured. The results 
indicated that only trace levels of curcumin and its metabolites were present in the liver and 
in circulation and the order of magnitude was too less to exert pharmacological effects 
(Garcea et al., 2004). As a result of this constraint, research is now directed towards 
enhancing the bioavailability of curcumin. Animal and human studies suggest that 
administration of curcumin along with piperine / turmeric oil enhances its bioavailability 
(Bishnoi et al., 2010, Suresh &  Srinivasan 2010). Administration of curcumin along with 
piperine enables curcumin to stay for longer in the tissues. When administered with 
piperine, curcumin was detected in the brain at 24, 48 and 96 h and at 48 h the levels of 
curcumin in the brain exceeded that found in the kidney (5.87 g vs 1.16g) (Suresh &  
Srinivasan 2010). More recently, curcumin nanoparticles which are entirely water soluble 
have been suggested to enhance its bioavailability (Ray et al., 2011). Curcumin complexation 
with phosphatidyl choline (PC) and liposomal curcumin PC complex enhanced its 
bioavailability in terms of better absorption and improved pharmacokinetics (Gupta &  Dixit 
2011a, b).  
3.2 Antioxidant properties of curcumin 
The antioxidant activity of curcumin has been attributed to the various functional groups of 
curcumin. Jovanovic et al. suggest that the central methylenic group rather than the 
phenolic group is the H-atom donor, while others attribute its radical scavenging property 
to the phenolic group (Barclay et al., 2000, Priyadarsini et al., 2003) and the methoxy group 
further enhances this activity (Priyadarsini et al. 2003). The interactions between curcumin 
and biological relevant free radicals have been thoroughly investigated. Iwunze and 
McEwan demonstrated by biophysical techniques that curcumin directly detoxified the 
reactive nitrogen species peroxynitrite (PN) (Iwunze &  McEwan 2004). Our group 
demonstrated that curcumin can protect neuronal mitochondria against PN induced 
nitration and nitrosylation of brain mitochondrial proteins (Mythri et al., 2007). It was also 
shown that curcumin protected against PN induced protein nitration and inhibition of 
enzyme activity of mitochondrial complex I with implications for PD (Mythri et al. 2007). 
Recently, we demonstrated that curcumin protects against PN mediated loss of 
mitochondrial membrane potential and mitochondrial integrity and curcumin derivatives 
offered improved protection compared to curcumin (Mythri et al. 2011). Mishra et al 
demonstrated that at low superoxide concentrations, curcumin effectively caused 
superoxide dismutation without itself undergoing any chemical change, but at higher 
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concentrations of superoxide, curcumin inhibited superoxide activity by reacting with it 
(Mishra et al., 2004). The enol structure with the intramolecular hydrogen bond of curcumin 
strongly enhances the free radical scavenging activity (Ohara 2005, Toniolo et al., 2002). In 
vivo, the antioxidant activity of curcumin could be mediated through antioxidant enzymes 
such as superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx). Curcumin 
has been shown to serve as a Michael acceptor, reacting with GSH and thioredoxin (Adams 
et al., 2005). Curcumin has been found to be at least ten times more active as an antioxidant 
than even vitamin E (Khopde et al., 2000). The phenolic and the methoxy group on the 
phenyl ring and the 1,3-diketone system seem to be important structural features of 
curcumin that can contribute to these effects. The antioxidant activity of curcumin increases 
when the phenolic group has a methoxy group at the ortho position (Motterlini et al., 2000).  
3.3 Intracellular targets 
The important molecular targets of curcumin include growth factors, growth factor 
receptors, transcription factors, transcription factor receptors, cytokines, enzymes and genes 
which regulate apoptosis. Curcumin activates the NF-E2-related factor 2/ Antioxidant 
Response Element (Nrf2/ARE) pathway which in turn induces synthesis of phase II 
antioxidant  (Jeyapaul &  Jaiswal, 2000, Wild et al., 1999), glutathione-S-transferase (GST) 
(Chanas et al., 2002, Ye et al., 2007), NADH quinone oxidoreductase 1 (NQO1) (Ye et al., 
2007) and hemeoxygenase-1 (HO-1). Curcumin suppresses activation of the pro-survival 
transcription factor, nuclear factor kappa B (NFB) by inhibition of IB kinase (Jobin et al., 
1999, Plummer et al., 1999). Suppression of NFB leads to down regulation of cell cycle 
regulatory protein cyclin D1, cyclooxygenase 2 (COX2) and matrix metalloproteinase 9 
(MMP-9) (Shishodia et al., 2005). Curcumin further, suppresses interleukin 6 (IL-6) mediated 
signal transducers and activators of transcription (STAT-3) phosphorylation and its 
subsequent nuclear translocation (Bharti et al., 2003). Curcumin, it has been reported, 
activates the peroxisome proliferator activated receptor  (PPAR ) and hence mediates 
expression of cyclin D1 and epidermal growth factor receptor (EGFR) (Chen &  Xu, 2005). 
Curcumin down regulates the transcription factor, AP-1, by direct interaction with its DNA 
binding motif, (Bierhaus et al., 1997, Huang, T. S. et al., 1991) and also inhibits interleukin 1 
alpha (IL-1┙) and TNF-induced AP-1 activation (Xu, Y. X. et al., 1997). Moreover, curcumin 
targets the JNK pathway preventing JNK 1/2 and c Jun phosphorylation and caspase 3 
activation (Yu et al., 2010). Curcumin probably interferes with the signalling molecules at 
the same level or proximally upstream of MAPKKK level, hence indirectly affects the JNK 
pathway (Chen, Y. R. &  Tan 1998). Furthermore, curcumin induces anti apoptotic genes 
such as Bcl-2 and inhibits iNOS resulting in reduction of ROS, abrogates oxidative stress 
mediated cytochrome c release or caspase 3 activation, significantly increases levels of anti 
apoptotic proteins Bcl-2 and Bcl-xL and decreases levels of pro-apoptotic proteins Bax and 
Bad (Chen, J. et al., 2006, Chen, Y. R. &  Tan 1998). Curcumin treatment causes a 3-7 fold 
increase in the modifier subunit of the GSH synthesizing enzyme, gamma-glutamyl cysteine 
ligase (┛-GCL), in both the neurons and astrocytes (Dale &  Russell 1956, Lavoie, S. et al., 
2009) and enhances GSH levels (Jagatha et al., 2008) probably by enhancing astrocytic efflux 
of GSH (Stridh et al., 2010). In addition, curcumin regulates iron metabolism by activation of 
iron regulatory protein and repression of ferretin, suggesting a role as an iron chelator (Jiao 
et al., 2006, Jiao et al., 2009).  
Curcumin has been used as an antioxidant, antiseptic, anti-inflammatory, antibacterial and 
antitumor agent and has been used against various disorders such as arthritis, 
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cardiovascular diseases, lung fibrosis, gall stone formation, cardiotoxicity, diabetes, wound 
healing, AD and many more (Aggarwal 2006, Sharma et al., 2006). Recent studies have also 
shown curcumin to be protective against cancer (Duvoix et al., 2005), diabetes (Cheng et al., 
2009, Peeyush et al., 2009) and for the reduction of blood cholesterol (Alwi et al., 2008, Ejaz 
et al., 2009, Jang et al., 2008).  Curcumin protects against ischemia induced elevation in 
malondialdehyde (MDA) and lactate dehydrogenase (LDH) release in animal models 
(Dikshit et al., 1995). Faster restoration of muscle architecture upon curcumin treatment in 
injury models is probably mediated via NFB activation (Thaloor et al., 1999).  
3.4 Effects of curcumin in models of PD 
More recently, curcumin has found its role as a therapeutic agent in models of neurological 
disorders such as stroke and AD (Lim et al., 2001, Thiyagarajan &  Sharma 2004, Yang et al., 
2005). Lim et al. have shown that dietary curcumin reduces amyloid pathology, oxidative 
stress and pro-inflammatory markers in transgenic mice, in addition curcumin reduces the 
levels of GFAP, a marker of astrocytic proliferation (Lim et al. 2001). Further, curcumin not 
only prevented formation of abeta aggregates but could also disintegrate preformed 
aggregates by directly binding to plaques (Yang et al. 2005). Curcumin can cross the blood 
brain barrier and is found to be least toxic in human subjects at high doses (Lao et al., 2006, 
Qureshi et al., 1992, Shankar et al., 1980, Shoba et al., 1998). It can detoxify ROS, prevent 
protein aggregation and induce neurogenesis in vivo (Kim, S. J. et al., 2008, Priyadarsini et al. 
2003, Xu, Y. et al., 2007).  
Since PD is a neurological condition involving oxidative and nitrosative stress pathways, 
curcumin can serve as a potential therapeutic molecule for PD. Although thiol reducing 
agents such as GSH have been evaluated for their anti-PD activity, their efficiency is limited 
due to poor ability to cross the blood brain barrier (Bharath et al., 2002). Curcumin on the 
other hand can cross the blood brain barrier and can be administered at higher doses 
without the risk of toxicity. Curcumin treatment protects substantia nigra (SN) neurons, 
improves striatal dopamine levels and chelates Fe2+, following administration of 6-hydroxy 
dopamine (6-OHDA) in rats (Zbarsky et al., 2005). Curcumin treatment abrogates dopamine 
induced striatal neuron cell death (Luo et al., 1999). Curcumin treatment could further 
increase the density of dopaminergic neurons in the SN (Vajragupta et al., 2003). In all these 
studies, protection was afforded only by pretreatment with curcumin prior to 
administration of the toxin. A recent study in our laboratory indicated that chronic dietary 
consumption of turmeric caused an increase in the tyrosine hydroxylase (TH) positive 
neurons in the SN (Mythri et al. 2011). This is consistent with earlier reports suggesting that 
curcumin contributes to neurogenesis (Kim, S. J. et al. 2008, Xu, Y. et al. 2007). Similarly, our 
laboratory also demonstrated that curcumin derivatives with improved bioavailability offers 
better defense against 1-methyl-4-phenylpyridinium (MPP+) in dopaminergic neurons 
(Mythri et al. 2011). 
Curcumin treatment attenuates 3-nitropropionic acid mediated oxidative stress in vivo 
(Kumar, A. et al., 2007). PN is a highly labile reactive nitrogen species which inflicts severe 
cellular damage by nitrosative protein modifications. However, PN mediated nitrosative 
stress and mitochondrial dysfunction were attenuated by pretreatment with curcumin in 
vitro (Mythri et al. 2011). Curcumin mediated protection from PN toxicity is probably due to 
its direct interaction with and inactivation of PN in vitro (Iwunze &  McEwan 2004, Mythri et 
al. 2007) or indirectly by enhancing GSH levels in vivo ((Jagatha et al. 2008, Mythri et al. 
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2007). Curcumin down regulates iNOS which is probably mediated by the cJun/AP-1 
pathway (Brouet &  Ohshima 1995, Chan et al., 1998, Chen, J. et al. 2006). It has been 
suggested that curcumin binding to the AP-1 binding site on the promoter region of iNOS, 
results in its inactivation (Brouet &  Ohshima 1995). Pan et al.  have further reported that 
curcumin reduces iNOS mRNA levels and blocks induction of NFB (Pan, M. H. et al., 
2000). Rajeswari and colleagues have reported an increase in striatal dopamine and 
dihydroxy phenyl acetic acid (DOPAC) levels following curcumin injection in 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-injected mice (Rajeswari &  Sabesan 2008). In 
addition curcumin restores mitochondrial membrane potential, causes elevation in Cu-Zn 
SOD and modulates NFB nuclear translocation (Wang, J. et al., 2009a) by inhibition of IL6 
and TNF (Wang, S. L. et al., 2009b). Curcumin treatment inhibits AP-1 pathway by 
prevention of c-Jun phosphorylation (Luo et al. 1999) in addition to inhibition of JNK 
phosphorylation (Sawada et al., 2002, Yu et al. 2010) and caspase 3 activation (Yu et al. 2010). 
It has been reported that curcumin induces anti apoptotic genes such as Bcl-2 and inhibits 
iNOS resulting in reduction of ROS, abrogates oxidative stress mediated cytochrome c 
release or caspase 3 activation, significantly increases levels of anti apoptotic proteins Bcl-2 
and Bcl-xL and decreases levels of pro-apoptotic proteins Bax and Bad (Chen, J. et al. 2006, 
Chen, Y. R. &  Tan 1998). Curcumin induced cytoprotection was probably mediated by the 
Bcl-2 – mitochondria – reactive oxygen species (ROS) – iNOS pathway.  
Oxidative damage of lipids results in the formation of aldehydes such as 4HNE and MDA, 
which can integrate into lipid membranes resulting in disruption of membrane integrity, 
energy crisis and eventually cell death. Increased levels of 4HNE adducts have been 
reported in PD brains (Yoritaka et al., 1996). Lipid peroxidation mediated mitochondrial 
damage and apoptosis were abrogated by curcumin treatment and this was probably by 
checking cytochrome c release and caspase and PARP activation (Zhu et al., 2004). 
Curcumin was further able to protect from 4HNE mediated alterations in mitochondrial 
respiratory function and redox metabolism, cytochrome c release, DNA fragmentation and 
PARP activation in PC12 cells suggesting a protective function against lipid peroxidation 
mediated damage (Raza et al., 2008). 
Interestingly, not only is curcumin an antioxidant molecule but can also increase the levels 
of GSH, an endogenous antioxidant molecule, probably by enhancing astrocytic efflux of 
GSH (Stridh et al. 2010). Results from our laboratory and others have shown that curcumin 
enhances GSH levels in vitro and in vivo (Jagatha et al. 2008, Rajeswari 2006), in addition to 
enhancing the antioxidant enzyme activities of SOD and catalase in the striatum and mid 
brain of MPTP injected mice (Rajeswari 2006). In addition curcumin treatment results in a 3-
7 fold increase in the modifier subunit of the GSH synthesizing enzyme, ┛-GCL, in both the 
neurons and astrocytes (Dickinson et al., 2003, LaVoie, M. J. et al., 2005). Curcumin mediated 
increase in the transcription of GCL genes is probably via regulation of the binding of 
transcription factors to the 12-tetradecanoate 13-acetate (TPA)-responsive elements (TRE) 
and electrophilic response element (EpRE) elements (Dickinson et al. 2003). It further 
activates the Nrf2/ARE pathway which in turn induces synthesis of phase II antioxidant 
enzymes such as GCL (Jeyapaul &  Jaiswal 2000, Wild et al. 1999), GST (Chanas et al. 2002, 
Ye et al. 2007), NQO1 (Ye et al. 2007) and HO-1. We have used diester derivatives of 
curcumin (di-piperoyl, di-valinoyl and di-glutamoyl) with a resultant enhanced protection 
against GSH depletion mediated oxidative stress and toxin induced cell death in a 
dopaminergic neuronal cell line (Harish et al., 2010, Mythri et al. 2011). Particularly the di-
glutamoyl derivative showed maximum protection due to its deesterification following 
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absorption thus providing glutamate as a precursor for GSH synthesis. Thus one could use 
such pro drugs with improved uptake and better radical scavenging properties to combat 
oxidative and nitrosative stress in various neurodegenerative disorders such as PD. 
Curcumin further inhibits aggregation of -synuclein in vitro (Pandey et al., 2008, Wang, M. 
S. et al., 2010) and aggregation of A53T mutant -synuclein in SH-SY5Y cells in a dose 
dependent manner. Curcumin, thus enhances -synuclein solubility rendering them non-
toxic (Pandey et al. 2008). It also exhibits neuro-restorative properties as shown by its ability 
to disintegrate preformed -synuclein fibrils (Ono &  Yamada 2006). Curcumin pre-
treatment resulted in a reduction in aggregation of synphilin-1, a component of Lewy 
neuritis seen during PD, as a function of rotenone induced nitrosative stress, in SH-SY5Y 
dopaminergic cells suggesting its efficacy in ameliorating nitrosative stress induced damage 
(Pal et al. 2011).   
Curcumin has been suggested to regulate proteins involved in iron metabolism. Increased 
brain iron content is a major risk factor for PD pathogenesis. It has been reported that the SN 
of PD brains has increased iron content (Sofic et al., 1988). Not only is iron responsible for 
the production of .OH radical, but also promotes dopamine autooxidation in the SN neurons 
resulting in the release of H2O2 (Ben-Shachar et al., 1995). It has been reported that curcumin 
induces activation of iron regulatory protein and repression of ferretin and a reduction in 
levels of hepcidin, suggesting a role as an iron chelator (Jiao et al. 2006, Jiao et al. 2009).  
Epidemiological studies have suggested that consumption of curcumin by the Asian Indians 
is probably the reason for the low incidence of AD / PD in India when compared to the 
Caucasians (Ganguli et al., 2000). A study exploring the effect of race and age on the 
prevalence of PD reported that there are approximately 40% less melanized nigral neurons 
in Indian brains when compared to Caucasian brains (Muthane et al., 1998). Furthermore, 
there was no change in the number of nigral neurons with advancing age in the Asian 
Indian population (Alladi et al., 2009). Hence the lower prevalence of PD in India despite 
lower numbers of nigral neurons suggests protective mechanism probably related to the 
dietary habits. Chronic consumption of spices such as turmeric provide antioxidant defense 
against various conditions such as diabetes and cancer (Sinha et al., 2003, Srinivasan 2005). 
We have recently demonstrated that chronic dietary consumption of turmeric ameliorated 
the MPTP induced neurotoxicity in mice (Mythri et al. 2011). Although curcumin is the most 
active ingredient of turmeric, it could be more effective in its natural milieu. Also the 
biological properties of natural extracts would probably be mediated by their various 
constituents rather than a single compound. Therefore it would be interesting to study the 
pharmacokinetics and pharmacodynamics of curcumin or the other biologically active 
components of turmeric in order to completely understand its mechanism of action. 
4. Resveratrol 
Resveratrol (3,5,4'-trihydroxy-trans-stilbene), a phytoalexin and a stilbenoid derived is a 
naturally occurring polyphenol with strong antioxidant properties (Baur &  Sinclair 2006, 
Fremont 2000). Resveratrol is a dietary polyphenol found in the skin of grapes, raspberries, 
mulberries, pistachios and peanuts under normal conditions and synthesized by other 
medicinal and edible plants under stress conditions (Rocha-Gonzalez et al., 2008, Saiko et 
al., 2008). It exists as cis- and trans- isomers which are either free or bound to glucose 
(Mattivi et al., 1995). The trans- form can undergo isomerisation to the cis- form when 
exposed to ultraviolet irradiation (Lamuela-Raventos et al., 1995). Experimental evidences in 
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vitro and in vivo have demonstrated the pharmacological potential of resveratrol in human 
diseases and aging with curative properties against neurodegenerative diseases (Rocha-
Gonzalez et al. 2008). 
4.1 Absorption of resveratrol 
The oral absorption of resveratrol in humans is thought to occur mainly by transepithelial 
diffusion. However, a major portion of resveratrol administered orally is excreted via feces 
and urine (Wenzel &  Somoza 2005). Following oral ingestion, trans-resveratrol is 
extensively metabolized in the enterocyte before it enters the blood and target organs. Since 
trans-resveratrol is photosensitive it is easily oxidized thus presenting unfavorable 
pharmacokinetics (Frozza et al., 2010). Extensive metabolism in the intestine and liver 
results in the bioavailability of resveratrol to be <1% and dose escalation and repeated dose 
administration does not significantly alter the bioavailability. Metabolic studies, both in 
plasma and in urine, have revealed that resveratrol is modified as glucuronides and sulfates. 
The sulfated and glucuronidated forms appeared within approximately 15 min of entering 
the bloodstream, and moderate consumption of red wine results in serum levels of 
resveratrol that barely reach the micromolar concentrations. In contrast, its metabolites, 
which may be the active principle, circulate in serum for up to 9 h (Saiko et al. 2008). 
However, reduced dihydroresveratrol conjugates, in addition to highly polar but unknown 
products, may account for ~ 50% of resveratrol following oral administration. Apart from 
the metabolism in the intestine and liver, colonic bacterial metabolism also contributes to 
resveratrol bioavailability (Walle 2011). Among these, extremely rapid sulfate conjugation 
by the intestine/liver appears to be the rate-limiting step in resveratrol's bioavailability. 
Although the systemic bioavailability of resveratrol is very low, accumulation of resveratrol 
in epithelial cells along the aerodigestive tract and potentially active resveratrol metabolites 
may still produce in vivo effects (North &  Verdin 2004). Since low bioavailability of 
resveratrol is a major obstacle to biomedical applications, efforts are in progress to improve 
the absorption and slow down its metabolism (Biasutto et al., 2010). Oral and intravenous 
(i.v.) administration of resveratrol in human volunteers revealed that the absorption 
following oral administration of 25 mg oral dose was at least 70%, with peak plasma levels 
of resveratrol and metabolites at 491 ± 90 ng/ml (about 2 M) and a plasma half-life of 9.2 ± 
0.6 h. However, only trace amounts of unchanged resveratrol (<5 ng/ml) could be detected 
in plasma and most of the oral dose was recovered in urine.  
4.2 Effects of resveratrol in models of PD 
Similar to curcumin, the effectiveness of resveratrol is due to its ability to simultaneously 
target multiple pathways and proteins and thus may be effective in restoring homoestasis in 
vivo. The most important property relevant in abrogation of neuronal damage is its 
antioxidant potential. This has been extensively studied in different models and most of 
them refer to the systemic effects (Kovacic &  Somanathan 2010). Experiments from our 
laboratory have showed that resveratrol prevented peroxynitrite mediated nitration of 
mitochondrial proteins and this was significantly higher compared to curcumin (Mythri et 
al. 2007). Apart from its antioxidant properties, resveratrol displays anti-cancer and anti-
inflammatory properties. The anti-cancer properties arise due its ability to inhibit multiple 
target enzymes including kinases, cyclooxygenases, ribonucleotide reductase and DNA 
polymerases. Similarly, resveratrol protects the cardiovascular system against ischemic-
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reperfusion injury, promotes vasorelaxation, protects the endothelium and displays anti-
atherosclerotic properties and other functions thereby strongly supporting its role in 
cardioprotection. Resveratrol displays different properties depending on its concentration 
and also on the target cell and its physiology (Saiko et al. 2008). Resveratrol and its 
derivatives have shown promise in AD therapy and other neurodegenerative disorders 
(Albani et al., 2010) and more specifically on the inhibition of ┚-amyloid peptide aggregation 
(Richard et al., 2011).  
Interestingly, resveratrol-mediated intracellular effects and protective mechanisms might be 
via its effects as an agonist of the sirtuins (also called SIRT or silent information regulator 
two-proteins), which belong to the histone deacetylase family (Pallas et al., 2008, Wang, F. et 
al., 2007, Zhuang et al., 2003). Sirtuins possess NAD+ dependent deacetylase activity and 
mono-ribosyltransferase activity and are found in most organisms (North &  Verdin 2004, 
Yamamoto et al., 2007). SIRT1 is a major modulator of metabolism and displays therapeutic 
properties (Finkel et al., 2009, Harikumar &  Aggarwal 2008, Karuppagounder et al., 2009). It 
has been hypothesized that by activating SIRT1, resveratrol modulates the activity of 
numerous proteins, including peroxisome proliferator-activated receptor coactivator-1alpha 
(PGC-1 alpha), the FOXO family, Akt (protein kinase B) and NFB (Pallas et al., 2009). The 
beneficial effects of resveratrol as an anti-aging compound are believed to be mediated via 
the activation of SIRT1 (Hung et al., 2010).  
Resveratrol administration in adult mice protected the SN dopaminergic neurons and 
striatal dopamine against the neurotoxic effects of MPTP (Anderson et al., 2006, Blanchet et 
al., 2008). Resveratrol administration also significantly protected mice from MPTP-induced 
motor coordination impairment, hydroxyl radical overloading, and neuronal loss with 
implications for PD therapy (Lu et al., 2008). In cell culture, treatment with resveratrol 
protected against MPP+ toxicity and oxidative damage by modulating the apoptotic markers 
(Bournival et al., 2009, Gelinas &  Martinoli 2002). It has also been demonstrated that 
resveratrol effectively blocked the proteolytic cleavage of PKC and kinase activity induced 
by MPP+. In BV-2 microglial cells activated with lipopolysaccharide (LPS), pretreatment 
with resveratrol suppressed pro-inflammatory cytokine production and nitric oxide release. 
It could be surmised that resveratrol protects against the dopaminergic neurodegeneration 
by modulating the PKC dependent proapoptotic signaling pathway and the inflammatory 
response in activated microglia (Gordon , 2010). Resveratrol significantly reversed the toxic 
effects of MPTP by increasing the levels of dopamine and its metabolites, GSH and activities 
of GPx and reducing lipid peroxidation along with enhanced behaviour performance 
indicating that resveratrol could target multiple pathways with therapeutic potential in PD 
(Anandhan et al., 2010). Interestingly, transfection with SIRT1 siRNA blocked MPP+-
induced apoptosis in SH-SY5Y cells indicating that the toxicity of MPP+ was mediated via 
SIRT1 and possibly through the regulation of another pro-apoptotic protein 
BCL2/Adinovirus E1B 19kDa Interacting Protein 2 (BNIP2). In a similar study, Alvira and 
colleagues showed that although resveratrol prevented MPP+ induced death of cortical 
neurons in culture, the effect was not mediated via SIRT1 activation, since sirtinol - a SIRT1 
inhibitor could not attenuate MPP+ toxicity (Alvira et al., 2007). Furthermore MPP+ 
decreased the expression of SIRT1 indicating that the antiapoptotic effects of resveratrol 
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Other in vitro studies have also demonstrated the effects of Resveratrol against different 
neurotoxins (Chao et al., 2008, Okawara et al., 2007, Outeiro et al., 2007). The therapeutic 
role of resveratrol has been demonstrated in 6-OHDA induced in vivo model of PD. 
Ultrastructural analysis showed that resveratrol alleviated 6-OHDA-induced chromatin 
condensation, mitochondrial dysfunction and vacuolization of SN dopaminergic neurons. 
Resveratrol also reduced the levels of COX-2 and TNF-┙ mRNA in the SN suggesting that 
resveratrol exerts its effects via reduced neuroinflammatory reaction (Jin, F. et al., 2008). 
Oral treatment with resveratrol and its liposomal form prevented oxidative damage, 
prevented neuronal damage and restored motor behaviour in a 6-OHDA rat model of PD 
(Khan et al., 2010, Wang, Y. et al., 2011). The study also showed that resveratrol liposome 
offered better therapeutic effect than free resveratrol due to increased bioavailability. 
Oxyresveratrol, a polyhydroxylated stilbene from mulberry showed improved protection 
against 6-OHDA compared to resveratrol owing to its antioxidant activity, blood-brain 
barrier permeability and water solubility (Chao et al. 2008). Pinostilbene, a methylated 
derivative of resveratrol showed improved cellular bioavailability and better defense 
against 6-OHDA neurotoxicity in neuronal cell culture (Chao et al., 2010b). Lee et al. 
demonstrated that resveratrol protected SH-SY5Y neuroblastoma cells from apoptosis 
induced by dopamine (Lee, M. K. et al., 2007). 
Experiments in rat primary midbrain neuron-glia cultures demonstrated that resveratrol 
protected dopaminergic neurons against LPS-induced neurotoxicity in a dose and time-
dependent manner via inhibition of microglial activation and suppression of release of 
proinflammatory factors. The anti-inflammatory effects and therapeutic effects against LPS 
toxicity was attributed to the inhibition of NADPH oxidase-dependent generation of 
reactive oxygen species and attenuation of translocation of the cytosolic subunit (p47) of 
NADPH oxidase to the cell membrane. This mechanism was substantiated when resveratrol 
was not effective in cultures from NADPH deficient mice.  This is also related to an 
attenuation of MAPK and NFB signalling pathways in microglia (Zhang, F. et al., 2010). 
Bureau and colleagues demonstrated that resveratrol reduced apoptotic neuronal cell death 
induced by neuroinflammation in an LPS cell model and strongly decreased the mRNA 
expression of two proinflammatory genes, IL-1┙ and TNF-┙ (Bureau et al., 2008).  
Administration of a botanical extract (Regrapex-R) prepared from whole grape Vitis vinifera 
and Polygonum cuspidatum, enriched with polyphenols including resveratrol, to a drosophila 
transgenic model of PD overexpressing alpha-synuclein caused dose-dependent scavenging 
effects on ROS, protected mitochondria from oxidative damage and improved locomotor 
dysfunction and extended lifespan (Long et al., 2009). Resveratrol was able to protect  
neuronal cells in culture against toxicity arising from two aggregation-prone proteins, the 
AD-involved amyloid-beta (1-42) peptide (Abeta42) and the familiar PD linked alpha-
synuclein (A30P) [alpha-syn(A30P)] (Albani et al., 2009).  
5. Tea polyphenols 
Tea is one of the most frequently consumed beverage of the world. Out of the 2.5 million 
metric tons of dried tea manufactured annually, ~20 % is green tea, which is mainly 
consumed in China and Japan and ~78 % is black tea, which is consumed in Western 
countries (Chen, L. et al., 1997). Although consumption of tea as an ancient beverage and a 
lifestyle habit has been recognized, its potential pharmacological actions beneficial to human 
health have been recently reported (Weinreb et al., 2004). Human epidemiological and 
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animal experiments indicate that consumption of green and black tea might protect the 
brain against aging and reduce the incidence of dementia, AD and PD, which might be one 
of the mechanistic factors underlying the significantly lower rates of age-related 
neurological disorders among Asians compared to European or American populations 
(Mandel, S. A. et al., 2008). Green tea is non-fermented and contains mainly catechins that 
accounts for 30-40% of its dry weight. Catechins are polyphenols that have been suggested 
to contribute to the therapeutic properties of green tea. On the contrary, black and red teas 
are extensively fermented and oolong tea is semi-fermented which catalyzes the oxidation 
and polymerization of catechins thereby reducing their content to 3-10 % of dry weight. The 
catechins from green tea are polyphenols representing flavonoids. The eight major catechins 
of green tea are (+)-catechin (C), (+)-catechin gallate, (+)-gallocatechin, (+)-gallocatechin 
gallate, (-)-epicatechin (EC), (-)-epicatechin gallate (ECG), (-)-epigallocatechin (EGC), and 
(-)-epigallocatechin gallate (EGCG) (+ and – represent cis and trans isomers respectively). 
EGCG is the most abundant catechin (Higdon &  Frei 2003). Green tea in addition to 
catechins contain 2-3% of caffeic acid and 1-6% of amino acids (theanine constitutes about 
50% amino acid content) (Higdon &  Frei 2003). 
5.1 Absorption 
The in vivo metabolism of green tea catechins has been very well documented in humans 
and laboratory animals (Li, C. et al., 2000, Pietta et al., 1998). In humans, orally administered 
catechins are absorbed, metabolized and largely excreted within 24 h. Catechins were 
detected in rat plasma and bile as free or sulphated and glucuronidated conjugates (Harada 
et al., 1999). The bioavailability of green tea polyphenols in vivo depends on the route of 
administration. After intragastric administration of decaffeinated green tea (DGT) (200 
mg/kg) in rats, 13.7 % of EGC and 31.2 % of EC were shown in the plasma, but only 0.1% of 
EGCG was bioavailable (Chen, L. et al. 1997). Intravenous injection of DGT (25 mg/kg) 
showed that, the beta-elimination half-lives of EGCG, EGC, and EC were 212, 45, and 41 min 
respectively (Chen, L. et al. 1997). Recent studies have suggested that the EC metabolites 
such as epicatechin glucuronide and 3’–O-methylated epicatechin glucuronide formed after 
oral ingestion in rats were detectable in the brain (Abd El Mohsen et al., 2002). The results 
from the distribution study suggest that EGCG is mainly excreted through bile, and that 
EGC and EC are excreted through both the bile and urine (Spencer 2003). 
5.2 Antioxidant functions of tea polyphenols 
There is growing evidence that catechins exert protective role in neurodegeneration. Several 
studies have suggested that the potential curative and therapeutic effects of tea polyphenols 
could be attributed to their free radical scavenging capacity. Catechins are powerful 
hydrogen donating antioxidants and scavengers of reactive oxygen and nitrogen species in 
vitro (Lee, S. et al., 2000, Matsuoka et al., 1995, Oliver et al., 1990). Tea polyphenols may also 
regulate antioxidant enzymes like SOD and catalase in mouse striatum (Levites et al., 2001). 
Progressive iron accumulation in SN pars compacta of PD patients is well established and is 
considered to be a major contributor to oxidative stress (Gerlach et al., 1994, Riederer et al., 
1989). Green tea polyphenols can stoichiometrically bind ferric iron to form an inactive iron 
polyphenol complex (Grinberg et al., 1997). In rat brain tissue, green tea and black tea 
extracts were shown to inhibit lipid peroxidation promoted by iron ascorbate in 
homogenates of brain mitochondrial membranes (Levites et al., 2002b). EGCG inhibited 
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paraquat-induced MDA production in rat liver microsomes by scavenging superoxide 
radicals and by iron chelating activity (Liou et al., 2001).  
5.3 Functions of tea and its constituent polyphenols in PD 
Several prospective studies have assessed the association between coffee/tea consumption 
and PD risk, but the results are inconsistent. Kandinov and colleagues carried out a 
retrospective study on 278 consecutive PD patients and assessed the data on smoking and 
coffee or tea consumption and found that disease progression was not affected by cigarette 
smoking, tea or coffee consumption (Kandinov et al., 2007). In contrast, the same group 
demonstrated that cigarette smoking, coffee and tea drinking may protect against PD and 
delay the onset of disease (Kandinov et al., 2009). According to their study in human 
patients, while consumption of more than 3 cups of tea per day delayed the onset of motor 
symptoms by 7.7 years, coffee consumption advanced the age of PD onset by 4.8 years. In a 
related study, Barranco Quintana and colleagues compiled data from human studies carried 
out by different groups and observed a clear protective effect of tea consumption and this 
protective effect was more evident in the Chinese populations (Barranco Quintana et al., 
2009). They also suggest that the low rate of tea consumption among persons with PD could 
provide valuable insight into the pathology. A population based study in ethnic Chinese to 
understand the role of environmental factors and dietary intake demonstrated that while 
there was a dose-dependent protective effect of PD in coffee and tea drinkers and smokers, a 
history of exposure to heavy metals increased the risk of PD (Tan, E. K. et al., 2003). Tan et 
al. observed that while black tea, a caffeine-containing beverage, showed an inverse 
association with PD risk, green tea drinking was unrelated to PD (Tan, Louis C. et al., 2008). 
A study among Finnish subjects indicated that coffee drinking is associated with a lower 
risk of PD and increased tea consumption is associated with a lower risk of PD (Hu et al., 
2007). Since most of these studies are based on survey among PD patients, it would be 
difficult to draw significant conclusions.  
However, experiments in cell and animal models have clearly indicated the therapeutic 
effects of tea extracts and its constituent catechin, EGCG against PD. These curative 
properties might be due to their ability to act as antioxidants, modulators of intracellular 
neuronal signalling, metabolism, cell survival/death genes, and mitochondrial function 
(Mandel, S. A. et al. 2008, Mandel, S. A. et al., 2011). With reference to PD therapy, EGCG 
has a dual therapeutic effect in vivo (Kang et al., 2010). Firstly, EGCG is a naturally occurring 
catechol-O-methyl transferase (COMT) inhibitor which strongly inhibited human liver 
COMT-mediated O-methylation of L-DOPA in a dose-dependent manner and decreased the 
accumulation of 3-O-methyldopa in the plasma and striatum in vivo following oral 
administration of L-DOPA + carbidopa. In addition, EGCG also protected against 
glutamate-induced oxidative cytotoxicity in hippocampal cultures through inactivation of 
the NFB-signaling pathway in vitro and against kainic acid-induced oxidative damage and 
neurodegeneration in the hippocampus in vivo.  
Many studies related to therapeutic effects of tea polyphenols in PD have been carried out in 
the Parkinsonian model involving the neurotoxin 6-OHDA and have obtained varied 
results. Rats treated with black tea either prior to or after 6-OHDA provided significant 
protection in terms of behavioural and motor functions, antioxidant levels, apoptotic 
markers, dopaminergic neuronal numbers and expression of tyrosine hydroxylase (TH). 
However, the degree of improvement in motor and neurochemical deficits was more 
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prominent in 6-OHDA rats pre-treated with the extract (Chaturvedi et al., 2006). Green tea 
polyphenols protected SH-SY5Y neuroblastoma cells against apoptosis induced by 6-OHDA 
as evidenced by lowered apoptotic markers, restoration of mitochondrial integrity, 
decreased oxidative damage and intracellular free Ca2+ and inhibition of auto-oxidation of 6-
OHDA. Further, the cells were protected against 6-OHDA-induced increase in levels of NO 
and protein nitration, and over-expression of neuronal NOS (nNOS) and iNOS. These 
results indicate that green tea polyphenols ameliorate 6-OHDA toxicity via attenuation of 
the ROS-NO pathway (Guo et al., 2005). The same group confirmed these effects against 6-
OHDA in vivo in mid brain and striatum again emphasizing the involvement of the ROS-NO 
pathway (Guo et al., 2007). In order to identify the active ingredient against 6-OHDA, five 
catechins [EGCG, ECG, EGC, EC and (+)-C] representing the most prominent tea 
polyphenols were compared with regard to their effects on 6-OHDA-induced apoptosis in 
PC12 cells and the protective effects of the five catechins were in the order ECG > EGCG > 
EC > (+)-C > EGC and the antiapoptotic activities appear to be structurally related to the 3-
gallate group (Jin, C. F. et al., 2001, Nie et al., 2002). In a related study, it was showed that 
EGCG protected against 6-OHDA via stimulation of PKC and modulation of cell 
survival/cell cycle genes such as Bax, Bad, Mdm2, Bcl-2, Bcl-w, and Bcl-x(L) and also by 
potent antioxidant and iron chelating actions thereby preventing nuclear translocation and 
activation of cell death promoting NFB (Levites et al., 2002a). Since the stability and 
bioavailability of EGCG are restricted, Chao et al. generated and tested a pro-drug 
representing a fully acetylated EGCG (pEGCG) in a PD cell model (Chao et al., 2010a). They 
found that pEGCG displayed improved protection compared to EGCG against 6-OHDA 
toxicity in SH-SY5Y neuroblastoma cells probably via activation of Akt pathway and 
reduced caspase-3 activity. In contrast, when Leaver et al. administered rats with EGCG for 
14 days followed by exposure to 6-OHDA, they observed that EGCG produced subtle 
symptomatic relief in lesioned animals and could not prevent neuronal damage to a 
significant extent (Leaver et al., 2009).  
Tea extracts and EGCG have displayed therapeutic effect in other toxic models of PD. Tea 
extract and EGCG protected against MPTP mediated dopamine loss and neurotoxicity in 
vivo and this effect could be mediated by inhibition of NOS (Choi et al., 2002, Kim, J. S. et al., 
2010, Li, R. et al., 2006). In a related study, it was demonstrated that green tea extract and 
EGCG protected against MPTP neurotoxicity via antioxidant effects and inhibition of 
monoamine oxidase-B (MOAB) (Levites et al. 2001). Mechanistically, green tea polyphenols 
can ameliorate neuronal damage via inhibitory effects on dopamine transporters (DAT), 
through which they block MPP+ uptake and protect dopaminergic neurons against MPP+-
induced injury (Pan, T. et al., 2003). Similarly, Hou et al. (2008) demonstrated that EGCG 
attenuated cell death in PC12 cells induced by the herbicide and PD toxin paraquat (PQ) by 
maintaining mitochondrial membrane potential, inhibiting caspase-3 activity and down 
regulating the expression of pro-apoptotic protein second mitochondrial-derived activator 
of caspase (SMAC) in cytosol. However, in rotenone-treated mesencephalic cultures and 
organotypic striatal cultures, EGCG protected striatal slices to a limited extent by 
counteracting NO production by rotenone but was not significantly effective against 
rotenone toxicity in mesencephalic cultures (Moldzio et al., 2010). 
Green tea could also protect against environmental toxin-induced cell injury and 
neuroinflammation with implications for PD.  Tai and Truong (2010) reported that EGCG 
reduced dichlorodiphenyl-trichloroethane (DDT)-induced cell death in dopaminergic SH-
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SY5Y cells suggesting that EGCG might activate a protective mechanism that might alleviate 
organochlorine pesticide-induced cell injury. Likewise, EGCG also inhibited LPS-activated 
microglial secretion of NO and TNF-┙ through the down-regulation of iNOS and TNF-┙ 
expression thereby protecting against neuroinflammation and injury in dopaminergic 
neurons (Li, R. et al. 2004). The antioxidant property of EGCG is also beneficial against 
protein aggregation in PD. Iron induces toxic aggregation of monomeric alpha synuclein 
leading to neurodegeneration in dopaminergic neurons. In the MPTP model, iron 
accumulation is also linked to NO-dependent mechanism. Mandel et al. showed that EGCG 
prevented the accumulation of iron and alpha-synuclein in SN thereby preventing neuronal 
damage (Mandel, S. et al., 2004). However, green tea and its constituent polyphenols could 
not protect PC12 cells against L-glutamate and MPP+ (Mazzio et al., 2001).  
6. Conclusions 
Most of the drugs currently used in PD therapy replenish the brain dopamine and provide 
symptomatic relief during early PD. However, many patients develop motor complications 
with chronic treatment. Further, these drugs do not slowdown or prevent the progression of 
the disease since their ability to prevent neuronal damage has not been comprehensively 
validated in humans. Therefore, novel therapies with possible curative properties are being 
exploited for adjunctive therapy. It is well documented that neurodegeneration in PD is 
contributed by several interrelated disease pathways but the molecular mechanisms of their 
relationships and their chronology have not been completely understood. Therefore, any 
molecule(s) with therapeutic potential in PD should be simultaneously effective against 
multiple pathways. In this regard, several in vitro and in vivo studies using PD models have 
tested natural antioxidants and molecules for their ability to protect against 
neurodegeneration with implications for therapy. The most prominent are the polyphenolic 
antioxidants obtained from plant sources. Most of these compounds display antioxidant, 
anti-inflammatory and anti-cancer properties, cross the blood-brain barrier and prevent 
neuronal damage in neurological disorders. Recent studies strongly support the clinical 
application of these compounds in PD. The current chapter explores the therapeutic 
potential of polyphenols such as curcumin, resveratrol and tea polyphenols in PD. These 
three polyphenols share common biological properties including antioxidant function, low 
toxicity and therapeutic benefits in the brain of different PD models. The available data 
indeed indicate that these polyphenols could have therapeutic potential in PD. Although 
several studies have been carried out in the recent years, the biological properties and health 
benefits of these polyphenols have not been completely understood. However, the most 
important limiting factor for the therapeutic application of these compounds in PD is their 
limited bioavailability in vivo. Further, the delivery of compounds specifically to mid-brain 
dopaminergic neurons for maximum therapeutic effect has not been completely 
standardized. Apart from this, studies are also needed to test the safety and efficacy in 
humans to translate the experimental results for therapeutic application in PD patients. 
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